10-K/A: OneMedNet Restates 2023 and 2022 Financials Following Accounting Errors and Auditor Suspension

OneMedNet Corporation restated its 2023 and 2022 financial statements due to accounting errors and the suspension of its previous auditor, BF Borgers CPA PC.

Summary

• OneMedNet Corporation has filed an amended annual report to restate its financial statements for the years ended December 31, 2023 and 2022.
• The restatement was necessary due to errors in accounting for convertible notes, warrants, stock-based compensation, and the de-SPAC transaction.
• The company's previous auditor, BF Borgers CPA PC, was suspended by the SEC, leading to the engagement of WithumSmith+Brown, PC for a re-audit.
• The company reported net losses of $33.8 million and $30.5 million for 2023 and 2022, respectively.
• Subscription revenue increased by 29% in 2023, while web imaging revenue decreased by 70%.
• One significant customer accounted for 51% and 29% of the company's revenue in 2023 and 2022, respectively.
• The company's auditors have expressed concern about its ability to continue as a going concern.
• The company is seeking additional capital through equity and debt financing arrangements.

Sentiment

Score: 3

Explanation: The document reveals significant financial and operational challenges, including restated financials, auditor issues, going concern doubts, and Nasdaq listing compliance issues. While there are some positive aspects, the overall tone is negative from an investment perspective.

Positives

• Subscription revenue increased by 29% in 2023.
• The company has a growing federated network of 95+ healthcare facilities.
• The company has a team of highly experienced and clinically trained data curators.
• The company is a leader in the field of regulatory-grade imaging RWD curators.
• The company has a robust compliance program aimed at ensuring it operates in compliance with all existing legal requirements.

Negatives

• The company experienced net losses of $33.8 million in 2023 and $30.5 million in 2022.
• Web imaging revenue decreased by 70% in 2023.
• The company's auditors have expressed concern about its ability to continue as a going concern.
• The company is dependent on a single customer for a significant portion of its revenue.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company has received multiple notices from Nasdaq for not meeting listing requirements.

Risks

• The company has a history of operating losses and may never achieve profitability.
• The company's ability to continue as a going concern is dependent on its ability to generate cash flows and obtain financing.
• The company relies heavily on one significant customer, and the loss of this customer could significantly impact revenue.
• The company may encounter difficulties in managing its attempted growth.
• The Real World Data and Real World Evidence market is highly competitive.
• The company may be unable to attract and retain key employees and qualified personnel.
• The company's information systems are vulnerable to security breaches and cyber-attacks.
• The company may be unable to adequately protect or expand its intellectual property.
• The company's operations are subject to extensive government regulation and oversight.
• The company's collection, use, and disclosure of personal information is subject to privacy and security regulations.
• The company's operations could be damaged by natural disasters and other catastrophic events.
• The company's ability to utilize net operating loss and tax credit carryforwards may be subject to limitations.
• The company is subject to many hazards and operational risks that may not be fully covered by insurance.
• The company's Common Stock may be subject to extreme volatility.
• The company may be unable to maintain listing of its securities on Nasdaq.
• The company's principal stockholders will continue to have significant influence over the company.
• The company could be subject to securities class action litigation.
• The company does not expect to pay dividends in the foreseeable future.
• The company is an emerging growth company, and the reduced reporting requirements may make its Common Stock less attractive to investors.
• Anti-takeover provisions could impair a takeover attempt.
• The company's management has limited experience in operating a public company.
• The company has incurred and will continue to incur significant increased expenses and administrative burdens as a public company.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company may not be able to raise additional capital on attractive terms.
• The company may redeem unexpired warrants prior to their exercise at a time that is disadvantageous to warrant holders.

Future Outlook

The company intends to continue funding its operations through equity and debt financing arrangements and expects to continue incurring operating losses and negative cash flows in the future. The company plans to expand its sales network, enhance its service offering, and expand its product portfolio.

Management Comments

• Management hopes to raise cash either through a public offering or private debt and equity offering.
• Management plans to raise additional working capital through an equity or debt offering and ultimately attain profitable operations to fulfill its operating and capital requirements for at least 12 months from the date of the issuance of the consolidated financial statements.

Industry Context

The global Real World Evidence solutions market is expected to grow at a compound annual growth rate (CAGR) of 8.4% from 2024 to 2030, driven by increasing demand for enhanced Real World Evidence capabilities within the life science industry. The market is shifting from volume to value-based care, and government initiatives are supporting Real World Evidence programs.

Comparison to Industry Standards

• The document does not provide specific comparable companies or projects for a detailed comparison.
• However, the document does mention that the global Real World Evidence solutions market is estimated at $2.6 billion in 2023 and is expected to grow at a CAGR of 8.4% from 2024 to 2030.
• The company's revenue of $1.021 million in 2023 is significantly lower than the overall market size, indicating that the company is still in an early stage of growth.
• The company's focus on regulatory-grade imaging RWD is a niche area within the broader RWE market, which may provide a competitive advantage but also limits its addressable market.

Management Changes

Related Party Transactions

• The company issued PIPE Notes and warrants to related party investors.
• The company issued Convertible Promissory Notes and warrants to related party investors.
• The company entered into shareholder loans with related party investors.
• The company assumed loan extensions to related parties in connection with the Business Combination.

Stakeholder Impact

• Shareholders face significant risks due to the company's financial instability and potential delisting from Nasdaq.
• Employees may be affected by potential restructuring or layoffs due to the company's financial challenges.
• Customers may experience disruptions in service due to the company's financial instability.
• Suppliers and creditors face increased risk of non-payment due to the company's financial challenges.

Next Steps

• The company will continue to seek additional capital through equity and debt financing.
• The company will work to regain compliance with Nasdaq listing requirements.
• The company will focus on expanding its sales network, enhancing its service offering, and expanding its product portfolio.

Key Dates

Keywords

Real World Data, Real World Evidence, clinical imaging, healthcare data, regulatory-grade data, life sciences, data curation, financial restatement, auditor suspension, going concern, Nasdaq listing, convertible notes, warrants, stock-based compensation, de-SPAC transaction